Effects of Mithramycin on BCL11A Gene Expression and on the Interaction of the BCL11A Transcriptional Complex to γ-Globin Gene Promoter Sequences

• Published in: Genes Vol. 14; no. 10; p. 1927
• Main Authors: Finotti, Alessia, Gasparello, Jessica, Zuccato, Cristina, Cosenza, Lucia Carmela, Fabbri, Enrica, Bianchi, Nicoletta, Gambari, Roberto
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.10.2023; MDPI
• Subjects: Analysis; Antitumor agents; BCL11A; beta-Thalassemia - genetics; Blood diseases; Cells; Cloning; CRISPR; Erythroid cells; Ewings sarcoma; fetal hemoglobin; Fetal Hemoglobin - genetics; Fetal Hemoglobin - metabolism; Fetuses; gamma-Globins - genetics; gamma-Globins - metabolism; Gene Expression; Gene regulation; Genes; Genetic aspects; Genetic transcription; globin genes; Hemoglobin; Humans; Kruppel-Like Transcription Factors - genetics; Leukemia; Membranes; mithramycin; Oct-4 protein; Plicamycin - pharmacology; Promoters (Genetics); Proteins; Repressor Proteins - genetics; Repressors; Sickle cell anemia; Sickle cell disease; Thalassemia; Transcription; Transcription factors; Transcription Factors - genetics; Tumors; β-thalassemia; St Louis Missouri; United States > US; Italy; fetal hemoglobin; transcription; BCL11A; globin genes; mithramycin; β-thalassemia; HbF inducers

The anticancer drug mithramycin (MTH), has been proposed for drug repurposing after the finding that it is a potent inducer of fetal hemoglobin (HbF) production in erythroid precursor cells (ErPCs) from β-thalassemia patients. In this respect, previously published studies indicate that MTH is very a...